Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADC Therapeutics SARL

www.adctherapeutics.com

Latest From ADC Therapeutics SARL

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

IPO Update: 35 Biopharmas Provide -6.1% Average Return; New Offerings Feel Stock Market Impact

Only 16 drug developers that went public in the US during the first three quarters are trading in positive territory. While the IPO queue keeps growing, ADC Therapeutics and Monopar cite "market conditions" as they postpone their offerings.

Financing Business Strategies

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Financing Business Strategies

Finance Watch: High Value Of Exits Keep Biopharma VC Deals At Near-Record Levels

Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.

Financing Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • ADC Therapeutics SARL
  • Senior Management
  • Chris Martin, PhD, CEO
    Michael Forer, EVP, CFO
    Patrick van Berkel, PhD, SVP, R&D
    Jay Feingold, MD, PhD, SVP, CMO & Head, Oncology
  • Contact Info
  • ADC Therapeutics SARL
    Phone: 21 653 02 00
    Route de la Corniche 3B
    Biopole
    Epalinges, 1066
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register